Saxagliptin Market: Global Industry Analysis and Forecast to 2020
Diabetes is the chronic condition associated with abnormally high level of glucose in the blood. Insufficient or non production of insulin in pancreas causes diabetes. Globally, the incidence of diabetes is increasing significantly and it is becoming a major burden. According to World Health Organization (WHO), approximately 221 million people are suffering from diabetes. There are large numbers of blood glucose lowering drugs. Saxagliptin is an oral anti-diabetic agent known as DPP IV inhibitor. DDP IV inhibitor is an enzyme...
View full press release